Compare Essex Property Trust, Inc. (ESS) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Sana Biotechnology Inc — how do they compare? Essex Property Trust, Inc. trades at $298.49 (market cap $18.82B), while Sana Biotechnology Inc trades at $3.16 (market cap $987.94M). The key difference: Essex Property Trust, Inc. is far larger — about 19× Sana Biotechnology Inc's market cap, and Essex Property Trust, Inc. pays a 3.54% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ESS | SANA | |
|---|---|---|
Market Cap | $18.82B | $987.94M |
Sector | Real Estate | Health |
52-Week High | $298.33 | $5.92 |
52-Week Low | $239.61 | $2.68 |
Enterprise Value | $25.54B | $962.13M |
Dividend Yield | 3.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $297.29, down slightly by 0.28% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results expected soon. Fundamentals show robust profitability with a 30.03% net income margin and $669.67M net income for 2025, though valuation ratios like a P/E of 32.93 appear elevated. Recent news highlights sustainability initiatives and inclusion in the Russell Microcap Index.
The outlook for ESS is cautiously optimistic, supported by high West Coast rental demand and AI-driven employment growth. Risks include elevated debt levels and Seattle market weakness. Analysts are mixed with a $294.25 consensus price target, slightly below the current price, suggesting limited near-term upside amid solid operational performance.
Sana Biotechnology (SANA) trades at $3.225, down 9.66% on the day, reflecting market volatility despite a bullish technical signal and strong analyst support. The company shows significant financial losses with a -$244.17M net income for 2025 and negative cash flows, but has beaten earnings expectations in two of the last three quarters. Recent news highlights clinical progress in cell therapies and a $69M capital raise via an ATM facility in May 2026.
The investment case balances high-risk fundamentals against promising clinical developments and overwhelming analyst optimism. While substantial losses and cash burn present clear risks, the company's scientific advancements and 82% buy rating from analysts suggest potential long-term upside for risk-tolerant investors in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
